TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: OnabotulinumtoxinA as Treatment for Major Depressive Disorder in Adult Females

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Moderate to severe major depressive disorder~Exclusion Criteria:~* Prior treatment with botulinum toxin of any serotype for any reason~* Use of antidepressant medication for depression within 2 weeks of study~* Diagnosis of Myasthenia gravis, Eaton-Lambert Syndrome, Amyotrophic Lateral Sclerosis

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Placebo for onabotulinumtoxinA 50 U (Type: PLACEBO_COMPARATOR): Placebo (normal saline) for onabotulinumtoxinA 50 U injected into protocol-specified areas on Day 1.
- onabotulinumtoxinA 50 U (Type: EXPERIMENTAL): OnabotulinumtoxinA 50 U injected into protocol-specified areas on Day 1.
- Placebo for onabotulinumtoxinA 30 U (Type: PLACEBO_COMPARATOR): Placebo (normal saline) for onabotulinumtoxinA 30 U injected into protocol-specified areas on Day 1.
- onabotulinumtoxinA 30 U (Type: EXPERIMENTAL): OnabotulinumtoxinA 30 U injected into protocol-specified areas on Day 1.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Treatment Response of High-dose and Standard-dose Rabeprazole for Extra-esophageal Reflux.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age is over 20 years old, under 80 years old, men or women~* Patients who had experienced extra-esophageal symptoms of gastroesophageal reflux disease more than once a week within the last month prior to the start of the study~Exclusion Criteria:~* Patients administered with prokinetics, H2 receptor antagonists, proton pump inhibitors, anticholinergic drugs or non-steroid anti-inflammatory drugs prior to study in 4 weeks~* Patients administered with anti-thrombotic drugs~* Patients taking other investigational drugs or participating in other clinical studies in 4 weeks~* Patients with esophageal stricture, esophageal varix, Barrett's esophagus, peptic ulcer or gastrointestinal bleeding~* Patients with Zollinger-Ellison syndrome~* Patients with any kind of malignant tumor~* Patients with surgery related to gastroesophageal~* Patients with significant cardiovascular, pulmonary, heptic, renal, hemopoietic or endocrine system primary disease~* Patients with neuropsychiatric disorder, alcoholism, or drug abuse~* Women either pregnant or breast feeding

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- High-dose rabeprazole (Type: EXPERIMENTAL): Rabeprazole 20mg twice daily by mouth before breakfast and dinner for 8 weeks
- Standard-dose rabeprazole (Type: ACTIVE_COMPARATOR): Rabeprazole 20mg once daily by mouth before breakfast for 8 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Anakinra to Prevent Post-infarction Remodeling

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age \>18 years~* Acute (\<24 hours) onset of chest pain~* New or presumably new ST elevation on ECG~* Planned coronary angiography for percutaneous revascularization~Exclusion Criteria:~* Inability to give informed consent~* Late presentation (\>24 hours)~* Unsuccessful revascularization or urgent coronary bypass surgery~* Hemodynamic instability~* End-stage congestive heart failure (AHA/ACC stage C/D, NYHA class IV)~* Preexisting severe LV dysfunction (LVEF\<20%) or severe valvular disease~* Severe asthma~* Pregnancy ( pre-enrollment pregnancy test)~* Contraindications to cardiac MRI or cardiac angiography~* Severe coagulopathy (INR\>2.0, Platelet count\<50,000/mm3)~* Severe renal insufficiency (creatinine clearance \<30 ml/min/m2)~* Recent (\<14 days) use of anti-inflammatory drugs (NSAIDS excluded)~* Chronic inflammatory disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Anakinra (Type: EXPERIMENTAL): Anakinra 100 mg given daily by subcutaneous injection for 14 days
- Placebo (Type: PLACEBO_COMPARATOR): 0.67 ml of NaCl 0.9% solution

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Varenicline in Ambivalent Smokers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* At least 18 years old~* Able to get to research lab in Burlington, Vermont or Omaha, Nebraska~* Daily smoker~* Smoke at least 8 cigarettes per day~* No reduction in smoking in last 30 days~* No intention to quit in the next 30 days~* Never used Varenicline before~* Not currently using smoking cessation medications or nicotine replacement therapy~* Willing to use Varenicline for at least 2 weeks~* Fluent in English~Exclusion Criteria:~* Cannot be currently pregnant or breastfeeding~* Kidney disease~* Frequent nausea~* On certain medications for asthma and/or depression~* Another household member in study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Varenicline (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone in Participants With Prostate Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* In-patients or out-patients with histologically or cytologically confirmed adenocarcinoma of the prostate without neuroendocrine differentiation or small cell histology~* Have surgically or medically castrated, with testosterone levels of less than 50 nanogram per deciliter~* Have prostate-specific antigen (PSA) level of at least 5 nanogram per milliliter~* Be under PSA progression according to Prostate-Specific Antigen Working Group (PSAWG) eligibility criteria or objective progression by Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.0 criteria for participants with measurable disease after androgen deprivation~* Have Eastern Cooperative Oncology Group Performance Status (ECOG PS) score of 0 or 1~Exclusion Criteria:~* Has received other hormonal therapy, including any dose of finasteride, dutasteride, any herbal product known to decrease PSA levels or any systemic corticosteroid within 4 weeks prior to Cycle 1 Day 1 or has received ketoconazole for prostate cancer~* Has received radiotherapy, chemotherapy (including estramustine) or immunotherapy (including provenge) within 4 weeks, or single fraction of palliative radiotherapy within 2 weeks prior to Cycle 1 Day 1~* Has had surgery or local prostatic intervention within 4 weeks prior to Cycle 1 Day 1. In addition, any clinically relevant sequel from the surgery must have resolved prior to Cycle 1 Day 1~* Has clinically significant heart disease as evidenced by myocardial infarction, or arterial thrombotic events, severe or unstable angina, or New York Heart Association (NYHA) Class 3 to 4 heart disease or cardiac ejection fraction measurement of less than 50 percent within 6 months prior to Cycle 1 Day 1~* Has uncontrolled hypertension (systolic blood pressure greater than or equal to 160 millimeter of mercury or diastolic blood pressure greater than or equal to 95 millimeter of mercury)

- Gender: MALE
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Abiraterone plus Prednisolone (Type: EXPERIMENTAL): Abiraterone 1000 milligram (mg) oral tablets will be administered once daily along with 5 mg oral prednisolone tablet administered twice daily for 28-daily dosing cycles and will be continued until disease progression or unacceptable toxicity.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: To Verify the Efficacy of Z-338 in Subjects With Functional Dyspepsia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects showing at least one of the 4 symptoms (upper abdominal pain, upper abdominal discomfort, epigastric pain, epigastric burning) for at least 6 months before obtaining informed consent~* Subjects showing two or more of the following symptoms: upper abdominal pain, upper abdominal discomfort, post-prandial fullness, upper abdominal bloating, early satiety, nausea, vomiting and/or excessive belching for at least 3 months (one of them should be post-prandial fullness or early satiation)~* Bothersome symptoms should be post-prandial fullness, upper abdominal bloating or early satiety at the time of obtaining informed consent~Exclusion Criteria:~* Subjects with structural disease that is likely to explain the symptom (e.g., GERD, erosion, ulcer, hiatal hernia, bleeding, malignancy or Barrett's esophagus) confirmed by upper endoscopy at the obtaining informed consent~* Subjects have heartburn in last 12 weeks before obtaining informed consent~* Subjects with irritable bowel disease (IBS)~* Subjects with diabetes mellitus requiring treatment~* Subjects with serious anxiety disorder~* Subjects with depression and/or sleep disorder~* Subjects with biliary tract disease and/or pancreatitis (including chronic pancreatitis)

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- Z-338 (Type: EXPERIMENTAL): None
- placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Preoperative Radiochemotherapy With Hyperthermia for Locally Advanced Rectal Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria:~* Histologically confirmed Adenocarcinoma of the rectum (up to 10 cm from the anal verge)~* International Union Against Cancer stages II or III~* ECOG PS 0/2~* Informed consent~Exclusion Criteria:~* Congestive heart failure (NYHA III/IV)~* History of myocardial infarction within the last 6 months.~* AV Block III~* Total hip replacement or major metal pelvic implants~* Cardiac pacemaker~* Contraindications for radiochemotherapy~* Contraindications for surgical tumor resection~* Previous pelvic radiotherapy or chemotherapy~* Active chronic inflammatory bowel disease~* Collagenosis~* Congenital diseases with increased radiosensitivity~* Pregnancy or breastfeeding~* Secondary malignancies other than locally controlled basalioma or in-situ carcinomas Infiltration of the anal canal

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- RtChx + Hyperthermia (Type: EXPERIMENTAL): Radiotherapy: 5 x 1,8 Gy/Week, cumulative dose 50,4 Gy (ICRU) Chemotherapy: 5-fluorouracil d1-5 and d29-d33 Deep regional hyperthermia: 2x/week

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Assess Treatment With 2 Different Dosing Schedules of Trabectidin Administered to Patients With Advanced Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Have advanced liposarcoma or leiomyosarcoma that has metastasized (spread)~* Have a pathology specimen available for centralized review~* Have progressive or relapsed (reappearance of) disease, received treatment with anthracycline and/or ifosfamide before enrollment in study, and have at least one measurable tumor lesion~* Have adequate bone marrow, liver and kidney function~* Have Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1~Exclusion Criteria:~* Previous exposure to Yondelis i.v. formulation, ET-743 (ecteinascidin)~* Cancer that has metastasized (spread) to the central nervous system~* Active viral hepatitis or chronic liver disease~* Unstable cardiac (heart) condition including congestive heart failure or angina pectoris (heart pain), myocardial infarction (heart attack) within 1 year before enrollment~* History of another neoplastic (malignant or nonmalignant tumor) disease (except basal cell carcinoma or cervical carcinoma adequately treated), unless in remission for 5 years or more before enrollment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Yondelis weekly schedule (Type: EXPERIMENTAL): Yondelis weekly schedule: 0.58 mg/m2 administered as a 3-hour i.v. infusion on Days 1 8 and 15 of each 28-day treatment cycle. Patients will be pretreated with 10 mg of dexamethasone i.v. 30 minutes prior to each infusion.
- Yondelis once every 3 weeks schedule (Type: EXPERIMENTAL): Yondelis once every 3 weeks schedule: 1.5 mg/m2 administered as a 24-hour i.v. infusion on Day 1 of every 21-day treatment cycle. Patients will be pretreated with 20 mg of dexamethasone i.v. on Day 1 of each treatment cycle 30 minutes prior to each infusion.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) in Japanese Adults With Subgenotype 1b Chronic Hepatitis C Virus (HCV) Infection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Chronic HCV-infection prior to study enrollment~* Screening laboratory result indicating HCV subgenotype 1b infection~* Subject has plasma HCV RNA level greater than 10,000 IU/mL at Screening~* Voluntarily sign an informed consent~* Females must be practicing specific forms of birth control on study treatment, or be post-menopausal for more than 2 years or surgically sterile~Exclusion Criteria:~* Co-infection of Hepatitis B Virus (HBV), human immunodeficiency virus (HIV) or any HCV genotype other than subgenotype 1b~* Prior therapy with direct acting antiviral agents for the treatment of HCV, including telaprevir, simeprevir and boceprevir~* Any cause of liver disease other than chronic HCV-infection, including but not limited to the following: hemochromatosis; alpha-1 antitrypsin deficiency; Wilson's disease; autoimmune hepatitis; alcoholic liver disease; drug-related liver disease; clinically significant laboratory abnormalities; uncontrolled clinically significant disease, disorder or medical illness

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Substudy 1, Arm A: DB 2-DAA (Type: EXPERIMENTAL): Double-blind (DB) 150 mg ABT-450/100 mg ritonavir/25 mg ABT-267 (2 direct-acting antiviral agents \[2-DAA\]) once daily (QD) for 12 weeks in participants without cirrhosis
- Substudy 1, Arm B: DB Placebo, Followed by OL 2-DAA (Type: PLACEBO_COMPARATOR): DB placebo QD for 12 weeks followed by open-label (OL) 150 mg ABT-450/100 mg ritonavir/25 mg ABT-267 (2-DAA) QD for 12 weeks in participants without cirrhosis
- Substudy 2, Arm C: OL 2-DAA (Type: EXPERIMENTAL): OL 150 mg ABT-450/100 mg ritonavir/25 mg ABT-267 (2-DAA) QD for 12 weeks in participants with compensated cirrhosis

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Fifth-year Follow-up Study for the Phase IV Clinical Trial of Hepatitis A Vaccine in Healthy Children

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* All subjects who received inactivated or attenuated alive HAV vaccine in the previous trial~Exclusion Criteria:~* Subjects who refused to continue in the follow-up study

- Gender: ALL
- Minimum Age: 18 Months
- Maximum Age: 35 Months
- Healthy Volunteers: t

Study Arms:
- Inactivated HAV vaccine (Type: None): Inactivated vaccine: 0.5 ml per dose containing 250 u antigen, one dose
- Attenuated alive HAV vaccine (Type: None): Attenuated alive vaccine: 1.0 ml per dose containing 6.50 lgCCID50 alive virus, one dose

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Pharmacokinetics of AT-007 in Healthy Subjects and in Adult Subjects With Classic Galactosemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of Classic Galactosemia confirmed by evidence of absent or significantly decreased (\<1%) GALT activity in red blood cells and by GALT gene analysis~* Urine galactitol \>100 mmol/mol creatinine~* Galactose-restricted diet~Exclusion Criteria:~* Complications of CG resulting in disability that, in the opinion of the Investigator, may prevent the subject from completing all study requirements (e.g., severe neurological deficits, severe cognitive impairment, or severe language difficulty).~* Renal disease (eGFR \< 90 mL/min/1.73 m2 or albuminuria).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- AT-007 (Type: EXPERIMENTAL): AT-007 is a CNS and retina penetrant aldose reductase inhibitor.
- Placebo Comparator (Type: PLACEBO_COMPARATOR): Placebo is used as a comparator to the experimental arm.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Long-term Efficacy, Safety and Tolerability of Pramipexole in Patients With Idiopathic Moderate to Severe Restless Legs Syndrome (RLS)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Written informed consent consistent with International Conference on Harmonization - Good Clinical Practice (ICH-GCP) and local Institutional Review Board/Independent Ethics Committee (IRB/IEC) requirements obtained prior to any study procedures being performed and the ability and willingness to comply with study treatment regimen and to attend study assessments~2. Male or female out-patients aged 18-85 years~3. Diagnosis of idiopathic RLS according to the clinical RLS criteria of the International Restless Legs Syndrome Study Group (IRLSSG) \[P03-03355\]. All four criteria must be present to fulfil the diagnosis of RLS.~4. RLS symptoms present at least 2 to 3 days per week during the last 3 months prior to baseline (Visit 2)~5. IRLS total score \>15 at baseline (Visit 2)~Exclusion Criteria:~1. Women of child-bearing potential (i.e. premenopausal women, or postmenopausal women less than 6 months after last menses) who do not use during the clinical trial an adequate method of contraception such as: double barrier protection (e.g. diaphragm or condom and spermicide), intrauterine device, hormonal therapy (oral, injectable, or subcutaneous), or partner's surgical sterilization~2. Any woman of child-bearing potential not having a negative pregnancy test at screening~3. Breastfeeding women~4. Patients with known hypersensitivity to pramipexole or any other component of the investigational product or placebo tablets~5. Diagnosis of augmentation under previous pharmacological RLS treatment~6. Concomitant or previous pharmacologic therapy as follows: Any intake of dopamine agonists within 14 days prior to baseline (Visit 2); Any intake of levodopa within 14 days prior to baseline (Visit 2); Unsuccessful prior treatment with non-ergot dopamine agonists (e.g. pramipexole, ropinirole);

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Pramipexole (Type: EXPERIMENTAL): 4 weeks of flexible dose-titration (to optimise efficacy and tolerability), starting at 0.125 mg once daily with the potential to increase or decrease the dose in steps to 0.25 mg, 0.5 mg and 0.75 mg, with the final dose level subsequently fixed for 22 weeks.
- Placebo (Type: PLACEBO_COMPARATOR): 4 weeks of flexible dose-titration as for the investigational product; with the dose subsequently fixed for 22 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete